FDA
- Status: approved
PCSK9 inhibitor plus statin (PCSK9 inhibitor plus statin) regulatory status in United States.
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. FDA has authorised it.
Beijing Anzhen Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.